Stereotactic body radiotherapy to the lung primary lesion improves the survival of patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: A real-world study

被引：0

作者：

Wei, H. ^{[1
]}

Zhou, X. ^{[1
]}

Yang, H. ^{[1
]}

Gong, Y-L. ^{[2
,3
]}

Wang, J. ^{[1
]}

Xu, Y. ^{[1
]}

Zhou, L. ^{[1
]}

Xue, J. ^{[1
]}

Zou, B. ^{[4
]}

Zhang, Y. ^{[1
]}

Zhu, J. ^{[1
]}

Peng, F. ^{[1
]}

Huang, M. ^{[1
]}

Lu, Y. ^{[1
]}

Liu, Y. ^{[1
]}

机构：

[1] Sichuan Univ, Dept Thorac Oncol, West China Hosp, Chengdu, Peoples R China

[2] Sichuan Univ, Dept Thorac Oncol, Ctr Canc, West China Hosp, Chengdu, Peoples R China

[3] Sichuan Univ, West China Hosp, Ctr Canc, State Key Lab Biotherapy, Chengdu, Peoples R China

[4] Sichuan Univ, Sch Med, West China Hosp, Dept Thorac Oncol, Chengdu, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1832

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1227P

引用

页码：S973 / S973

页数：1

共 50 条

[1] Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study
Wei, Hao
Zhou, Xiaojuan
Yang, Hui
Gong, Youling
Wang, Jin
Xu, Yong
Zhou, Lin
Xue, Jianxin
Zou, Bingwen
Zhang, Yan
Zhu, Jiang
Peng, Feng
Huang, Meijuan
Lu, You
Liu, Yongmei
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (10) : 2589 - 2598
[2] Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study
Hao Wei
Xiaojuan Zhou
Hui Yang
Youling Gong
Jin Wang
Yong Xu
Lin Zhou
Jianxin Xue
Bingwen Zou
Yan Zhang
Jiang Zhu
Feng Peng
Meijuan Huang
You Lu
Yongmei Liu
Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2589 - 2598
[3] Stereotactic body radiotherapy to the lung primary lesion improves the survival of patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: A real-world study.
Liu, Yongmei
Wei, Hao
Zhou, Xiaojuan
Yang, Hui
Gong, Youling
Wang, Jin
Xu, Yong
Zhou, Lin
Xue, Jianxin
Wen, Zou Bing
Zhang, Yan
Zhu, Jiang
Peng, Feng
Huang, Meijuan
Lu, You
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Local Ablative Therapy Improves Survival in Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated with First-Line EGFR-TKIs
Xu, Q.
Liu, H.
Xu, Y.
Zhou, C.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S93 - S93
[5] Efficacy of early stereotactic body radiotherapy to the primary lung lesion in patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKIs
Tao, D.
Lei, H.
Tan, J.
Yang, D.
Jiang, Y.
Zhou, W.
Wang, Y.
Wu, Y.
ANNALS OF ONCOLOGY, 2023, 34
[6] Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs
Xu, Qinghua
Zhou, Fei
Liu, Hui
Jiang, Tao
Li, Xuefei
Xu, Yaping
Zhou, Caicun
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1383 - 1392
[7] Local Consolidative Radiation Prolongs Disease Control of Patients with Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated with First-Line EGFR-TKIs
An, N.
Wang, H.
Jing, W.
Zhu, H.
Yu, J.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E494 - E495
[8] Local Ablative Therapy Improves Survival in Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated with EGFR-TKIs
Xu, Q.
Zhou, F.
Liu, H.
Xu, Y.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S337 - S337
[9] Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study
An, Ning
Wang, Haoyi
Li, Ji
Zhai, Xiaoyang
Jing, Wang
Jia, Wenxiao
Kong, Li
Zhu, Hui
Yu, Jinming
ONCOTARGETS AND THERAPY, 2019, 12 : 8311 - 8318
[10] First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Ji, W.
Jiang, D.
Zhang, J.
Zhang, H.
Wang, Q.
Cang, S.
Li, X.
Tan, J.
Xiang, Y.
Li, X.
Liu, A.
Lu, S.
ANNALS OF ONCOLOGY, 2023, 34 : S1693 - S1693

← 1 2 3 4 5 →